We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to ...

DRI Healthcare Trust is also making a $5 million investment in KalVista, a biopharmaceutical company based in Cambridge, Massachusetts.

Directive Might Cause Massive Medicine Shortages Affecting Millions Of Patients Across Europe ...

Alvotech (ALVO) has released an update. Alvotech, in collaboration with Advanz Pharma, has announced the acceptance of its Marketing ...

ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm, today announced that internationally recognized ...

The Canadian healthcare-focused royalty company said Monday that the royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals was acquired for an ...

About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain ...

Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support.

Chemical stability: Many medications can be sensitive to pH changes. For instance, certain antibiotics and hormones can break down and lose their effectiveness if they’re not kept in the right pH ...

The initiative aims to generate about US$7 billion from medical product exports by 2027 Shanghai's municipal government seeks ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...